hotspot
It wasn’t supposed to work out this way for Brent Saunders.
Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.
advertisement
As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
For Medicare Advantage, Democrats want stronger protections around AI
Next article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Tori Bowie and the unacceptable rates of Black maternal death
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
